Perspectives on the COMPARE-1 Trial
Low Dose DCB Showed No Statistically Significant Difference in Patency versus Higher Dose DCB
Prof. Dierk Scheinert
PI COMPARE-1 Trial
University of Leipzig, Germany
Prof. Andrew Holden
Auckland University, New Zealand
COMPARE-1 Clinical Trial Overview
Protocol pre-specified interim analysis of first 150 patients (COMPARE pilot) after 12-months of follow-up presented at LINC 2018*
*Results from the 150 patients from the pilot phase. Overall trial will enroll up to 414 patients.
WANT TO KNOW MORE?
Join our Drug-Eluting Technologies Community
Sign Up for Product Updates
Receive the latest news of Drug Eluting TechnologiesSIGN UP